Literature DB >> 9649086

Neonatal group B streptococcal infection in a managed care population. Perinatal Group B Streptococcal Infection Study Group.

T A Lieu1, J C Mohle-Boetani, G T Ray, L M Ackerson, D L Walton.   

Abstract

OBJECTIVE: In a health maintenance organization population, we determined the incidence of early-onset (at less than or equal to 7 days) neonatal group B streptococcal (GBS) disease, the sensitivity and prevalence of labor risk factors, the adherence to a protocol for intrapartum antibiotics, and the costs for care of and outcomes of affected infants.
METHODS: Mothers and infants at four health maintenance organization hospitals in northern California in 1989 to 1995 were studied retrospectively using computerized databases and chart review. In 1994, two of the four hospitals had adopted protocols similar to the ACOG recommendations for intrapartum antibiotics for women with labor risk factors (preterm, temperature 100.4F or higher, or rupture of membranes (ROM) 18 hours or more).
RESULTS: Among the 79,940 live births, the incidence of early-onset neonatal GBS infection was higher among preterm than among term infants (3.1 compared with 0.9 per 1000). Before protocol adoption, 68% of 65 infants with GBS had mothers with labor risk factors. Approximately 18% of all mothers had labor risk factors: 7.7% had preterm delivery, and 10.6% had term delivery with fever and/or ROM 18 hours or more. At the two hospitals that adopted GBS protocols, GBS incidence was reduced from 1.3 per 1000 in the preprotocol period to 0.8 per 1000 in the postprotocol period (P=.08). Six cases of neonatal GBS occurred after protocol adoption. Of these, four were not preventable under the protocol and two might have been preventable if protocol had been followed. Three of the 19 preterm infants with group B streptococcal disease died.
CONCLUSION: Risk factor-based protocols hold some promise to reduce GBS disease, but clinical strategies to promote protocol adherence are needed.

Entities:  

Mesh:

Year:  1998        PMID: 9649086     DOI: 10.1016/s0029-7844(98)00147-1

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Physicians' prevention practices and incidence of neonatal group B streptococcal disease in 2 Canadian regions.

Authors:  H D Davies; C E Adair; A Schuchat; D E Low; R S Sauve; A McGeer
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

2.  Preventing group B streptococcal infections: new recommendations.

Authors:  H Dele Davies
Journal:  Can J Infect Dis       Date:  2002-07

3.  Preventing group B streptococcal infections: New recommendations.

Authors:  H Dele Davies
Journal:  Paediatr Child Health       Date:  2002-07       Impact factor: 2.253

4.  Invasive early-onset neonatal group B streptococcal cases--Alaska, 2000-2004.

Authors:  Louisa Castrodale; Bradford Gessner; Laura Hammitt; Marc-Andre Chimonas; Thomas Hennessy
Journal:  Matern Child Health J       Date:  2006-12-16

Review 5.  Laboratory detection of group B Streptococcus for prevention of perinatal disease.

Authors:  F J Picard; M G Bergeron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

6.  Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections.

Authors:  Anne Schuchat; Aaron Roome; Elizabeth R Zell; Heather Linardos; Sara Zywicki; Katherine L O'Brien
Journal:  Matern Child Health J       Date:  2002-06

7.  Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization.

Authors:  Mark A Turrentine; Mildred M Ramirez; Joan M Mastrobattista
Journal:  Infect Dis Obstet Gynecol       Date:  2009-12-13

8.  Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis.

Authors:  Gary M Ginsberg; Arthur I Eidelman; Eric Shinwell; Emilia Anis; Reuven Peyser; Yoram Lotan
Journal:  Isr J Health Policy Res       Date:  2013-02-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.